Ensembles of uncertain mathematical models can identify network response to therapeutic interventions

Molecular BioSystems

Volumn 6, Issue 11, 2010, Pages 2272-2286

  Luan, Deyan ^a   Szlam, Fania ^c   Tanaka, Kenichi A ^c   Barie, Philip S ^b   Varner, Jeffrey D ^a  

^a Cornell University   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THROMBIN;

ARTICLE; BIOLOGICAL MODEL; BIOSYNTHESIS; BLOOD; BLOOD CLOTTING; COMPUTER SIMULATION; DRUG EFFECT; HEMOPHILIA A; HUMAN; REPRODUCIBILITY; TIME; UNCERTAINTY;

BLOOD COAGULATION; COMPUTER SIMULATION; FACTOR IX; FACTOR VIIA; HEMOPHILIA A; HUMANS; MODELS, BIOLOGICAL; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; THROMBIN; TIME FACTORS; UNCERTAINTY;

EID: 77957918516     PISSN: 1742206X     EISSN: 17422051     Source Type: Journal    
DOI: 10.1039/b920693k     Document Type: Article

References (115)

1. H. Kitano Computational systems biology Nature 2002 420 206 210
2. H. E. Assmus R. Herwig K. H. Cho O. Wolkenhauer Dynamics of biological systems: role of systems biology in medical research Expert Rev. Mol. Diagn. 2006 6 891 902
3. C. A. Arnaud Systems biology's clinical future Chem. Eng. News 2006 84 17 26
4. J. E. Bailey Complex biology with no parameters Nat. Biotechnol. 2001 19 503 504
5. S. L. Diamond Systems biology to predict blood function J. Thromb. Haemostasis 2009 7 Suppl 1 177 80
6. H. R. Roberts D. M. Monroe J. A. Oliver J. Y. Chang M. Hoffman Newer concepts of blood coagulation Haemophilia 1998 4 331 334
7. K. Mann Biochemistry and physiology of blood coagulation Thromb. Haemostasis 1999 82 165 174
8. S. Butenas K. G. Mann Blood coagulation Biochemistry 2002 67 5 15
9. M. Schenone B. C. Furie B. Furie The blood coagulation cascade Curr. Opin. Hematol. 2004 11 272 277
10. P. L. Giesen U. Rauch B. Bohrmann D. Kling M. Roque et al., Blood-borne tissue factor: another view of thrombosis Proc. Natl. Acad. Sci. U. S. A. 1999 96 2311 2315
11. K. G. Mann M. E. Nesheim W. R. Church P. Haley S. Krishnaswamy Surface-dependent reactions of vitamin K-dependent enzyme complexes Blood 1990 76 1 16
12. Hemostasis and Thrombosis: Basic Principles and Clinical Practice, ed., S. Z. Goldhaber,,, R. W. Colman, and, A. W. Clowes,, Lippincott Williams and Wilkins, 2006
13. K. E. Brummel S. G. Paradis S. Butenas K. G. Mann Thrombin functions during tissue factor-induced blood coagulation Blood 2002 100 148 152
14. S. Butenas K. E. Brummel R. F. Branda S. G. Paradis K. G. Mann Mechanism of factor VIIa-dependent coagulation in hemophilia blood Blood 2002 99 923 930
15. G. K. Hansson Inflammation, atherosclerosis and coronary artery disease N. Engl. J. Med. 2005 352 1685 1695
16. K. A. Tanaka N. S. Key J. H. Levy Blood coagulation: hemostasis and thrombin regulation Anesth. Analg. (N.Y.) 2009 108 1433 46
17. E. Tuddenham and D. Cooper, The molecular genetics of haemostasis and its inherited disorders, volume 25 of Oxford monographs in medical genetics, Oxford University Press, 1994
18. M. P. Mannucci E. G. D. Tuddenham The hemophilias - from royal genes to gene therapy N. Engl. J. Med. 2001 344 1773 1780
19. J. Mitchell A. Phillott Haemophilia and inhibitors 1: diagnosis and treatment Nursing Times 2008 104 26 27
20. K. Tomokiyo Y. Nakatomi T. Araki K. Teshima H. Nakano et al., A novel therapeutic approach combining human plasma-derived factors viia and x for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with factor viia alone Vox Sang. 2003 85 290 299
21. S. I. Chavin D. M. Siegel T. A. Rocco J. P. Olson Acute mycardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor viii deficiency and a factor viii inhibitor Am. J. Med. 1988 85 245 249
22. G. A. Allen M. Hoffman H. R. Roberts D. M. Monroe Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia Br. J. Haematol. 2006 134 314 319
23. J. Schneiderman E. Rubin D. J. Nugent G. Young Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience Haemophilia 2007 13 244 248
24. U. Hedner Factor viia and its potential therapeutic use in bleeding-associated pathologies Thromb. Haemostasis 2008 100 557 562
25. M. Talbot H. C. Tien The use of recombinant factor viia in trauma patients J. Am. Acad. Orthop. Surg. 2009 17 477 81
26. J. M. Lusher H. R. Roberts G. Davignon J. H. Joist H. Smith et al., A randomized, double-blind comparison of two dosage levels of recombinant factor viia in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia a and b, with and without inhibitors. rfviia study group Haemophilia 1998 4 790 798
27. A. D. Shapiro G. S. Gilchrist W. K. Hoots H. A. Cooper D. A. Gastineau Prospective, randomised trial of two doses of rfviia (novoseven) in haemophilia patients with inhibitors undergoing surgery Thromb. Haemostasis 1998 80 773 778
28. A. D. Shapiro Recombinant factor viia in the treatment of bleeding in hemophilic children with inhibitors Semin. Thromb. Hemostasis 2000 26 413 419
29. A. D. Shapiro Single-dose recombinant activated factor vii for the treatment of joint bleeds in hemophilia patients with inhibitors Clin. Adv. Hematol. Oncol. 2008 6 579 586
30. Y. Komiyama A. H. Pedersen W. Kisiel Proteolytic activation of human factors ix and x by recombinant human factor viia: Effects of calcium, phospholipids and tissure factor Biochemistry 1990 29 9418 9425
31. M. A. Payne P. F. Neuenschwander A. E. Johnson J. H. Morrissey Effect of soluble tissue factor on the kinetic mechanism of factor viia: Enhancement of p-guanidinobenzoate substrate hydrolysis Biochemistry 1996 35 7100 7106
32. D. M. Monroe M. Hoffman J. A. Oliver H. R. Roberts Platelet activity of high-dose factor viia is independent of tissure factor Br. J. Haematol. 1997 99 542 547
33. M. Hoffman D. M. Monroe III H. R. Roberts Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII Blood Coag. Fibrin. 1998 9 S61 S65
34. H. R. Roberts D. M. Monroe G. C. White The use of recombinant factor VIIa in the treatment of bleeding disorders Blood 2004 104 3858 3864
35. H. R. Roberts M. Hoffman D. M. Monroe A cell-based model of thrombin generation Semin. Thromb. Hemostasis 2006 32 32 38
36. G. A. Allen E. Persson R. A. Campbell M. Ezban U. Hedner et al., A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia Arterioscler., Thromb., Vasc. Biol. 2007 27 683 689
37. J. C. Duchesne K. A. Mathew A. B. Marr M. R. Pinsky J. M. Barbeau et al., urrent evidence based guidelines for factor viia use in trauma: the good, the bad, and the ugly Am. Surg. 2008 74 1159 65
38. D. Luan M. Zai J. Varner Computationally Derived Points of Fragility of a Human Cascade are Consistent with Current Therapeutic Strategies PLoS Comput. Biol. 2007 3 1347 1359
39. K. S. Brown C. C. Hill G. A. Calero C. R. Myers K. H. Lee et al., The statistical mechanics of complex signaling networks: nerve groth factor signaling Phys. Biol. 2004 1 184 195
40. K. G. Gadkar J. Varner F. J. Doyle Model identification of signal transduction networks from data using a state regulator problem IEE Proc.: Syst. Biol. 2005 2 17 30
41. S. Butenas C. Veer K. G. Mann 'Normal' thrombin generation Blood 1999 94 2169 2178
42. R. N. Gutenkunst J. J. Waterfall F. P. Casey K. S. Brown C. R. Myers et al., Universally sloppy parameter sensitivities in systems biology models PLoS Comput. Biol. 2007 3 1871 1878
43. K. H. Cho S. Y. Shin W. Kolch O. Wolkenhauer Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNFα-Mediated NF-β-Signal Transduction Pathway Simulation 2003 79 726 739
44. J. Stelling E. D. Gilles F. J. Doyle III Robustness properties of circadian clock architectures Proc. Natl. Acad. Sci. U. S. A. 2004 101 13210 13215
45. T. Eissing F. Allgöwer E. Bullinger Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise IEE Proc.: Syst. Biol. 2005 152 221 228
46. S. Nayak S. Salim D. Luan M. Zai J. D. Varner Test of highly optimized tolerance reveals fragile cell-cycle mechanisms are molecular targets in clinical cancer trials PLoS One 2008 3 e2016
47. C. M. Danforth T. Orfeo K. G. Mann K. E. Brummel-Ziedins S. J. Everse The impact of uncertainty in a blood coagulation model Math. Med. Biol. 2009
48. L. You J. Yin Evolutionary design on a budget: robustness and optimality of bacteriophage T7 IEE Proc.: Syst. Biol. 2006 153 46 52
49. H. Kitano A robustness based approach to systems-oriented drug design Nat. Rev. Drug Discovery 2007 6 202 210
50. B. N. Kholodenko A. Kiyatkin F. J. Bruggeman E. Sontag H. V. Westerhoff et al., Untangling the wires: a strategy to trace functional interactions in signaling and gene networks Proc. Natl. Acad. Sci. U. S. A. 2002 99 12841 12846
51. E. Sontag A. Kiyatkin B. N. Kholodenko Inferring dynamic architecture of cellular networks using time series of gene expression, protein and metabolite data Bioinformatics 2004 20 1877 1886
52. A. Kremling S. Fischer K. Gadkar F. J. Doyle III T. Sauter et al., A Benchmark for Methods in Reverse Engineering and Model Discrimination: Problem Formulation and Solutions Genome Res. 2004 14 1773 1785
53. F. P. Casey D. Baird Q. Feng R. N. Gutenkunst J. J. Waterfall et al., Optimal experimental design in an EGFR signaling and down-regulation model IET Syst. Biol. 2007 1 190 202
54. D. Imberti C. Dall'asta M. G. Pierfranceschi Oral factor xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review Intern. Emerg. Med. 2009
55. D. Garcia Novel anticoagulants and the future of anticoagulation Thromb. Res. 2009 123 Suppl 4 S50 5
56. S. Jones X. Zhang D. W. Parsons J. C. H. Lin R. J. Leary et al., Core signaling pathways in human pancreatic cancers revealed by global genomic analyses Science 2008 321 1801 6
57. G. Lippi M. Franchini E. J. Favaloro Pharmacogenetics of vitamin k antagonists: useful or hype? Clin. Chem. Lab. Med. 2009 47 503 15
58. M. Anand K. Rajagopal K. R. Rajagopal A Model Incorporating Some of the Mechanical and Biochemical Factors Underlying Clot Formation and Dissolution in Flowing Blood Journal of Theoretical Medicine 2003 5 183 218
59. M. Anand K. Rajagopal K. R. Rajagopal A model for the formation and lysis of blood clots Pathophysiol. Haemostasis Thromb. 2005 34 109 20
60. Z. Xu N. Chen M. M. Kamocka E. D. Rosen M. Alber A multiscale model of thrombus development J. R. Soc. Interface 2008 5 705 22
61. J. Jesty W. Yin P. Perrotta D. Bluestein Platelet activation in a circulating flow loop: combined effects of shear stress and exposure time Platelets 2003 14 143 149
62. K. Naito K. Fujikawa Activation of human blood coagulation factor XI independent of factor XII J. Biol. Chem. 1991 266 7353 7358
63. S. A. Smith N. J. Mutch D. Baskar P. Rohloff R. Docampo et al., Polyphosphate modulates blood coagulation and fibrinolysis Proc. Natl. Acad. Sci. U. S. A. 2006 103 903 8
64. H. C. Hemker P. Giesen The calibrated automated thrombogram (cat): a universal routine test for hyper- and hypocoagulability Pathophysiol. Haemostasis Thromb. 2002 32 249 53
65. K. A. Tanaka F. Szlam C. P. Rusconi J. H. Levy In vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry Thromb. Haemostasis 2009 101 827 833
66. P. Carmeliet Clotting factors build blood vessels Science 2001 293 1602 1604
67. S. R. Coughlin Thrombin signalling and protease-activated recpetors Nature 2000 407 258 264
68. E. N. Sorensen G. W. Burgreen W. R. Wagner J. F. Antaki Computational simulation of platelet deposition and activation I. model development and properties Ann. Biomed. Eng. 1999 27 436 448
69. K. Fujikawa Historical perspective of factor XI Thromb. Res. 2005 115 441 450
70. P. N. Walsh D. Sinha A. Koshy F. S. Seaman H. Bradford Functional characterization of platelet-bound factor XIa: Retention of factor XIa activity on the platelet surface Blood 1986 68 225 230
71. P. A. von dem Borne J. C. Meijers B. N. Bouma Feedback activation of factor xi by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis Blood 1995 86 3035 42
72. S. J. H. Wielders S. Béguin H. Hemker T. Lindhout Factor XI-dependent reciprocal thrombin generation consolidates blood coagulation when tissue factor is not available Arterioscler., Thromb., Vasc. Biol. 2004 24 1138 1142
73. A. L. Kuharsky A. L. Fogelson Surface-mediated control of blood coagulation: The role of binding site densities and platelet deposition Biophys. J. 2001 80 1050 1074
74. K. G. Jones K. G. Mann A model for the tissue factor pathway to thrombin: II a mathematical simulation J. Biol. Chem. 1994 269 23367 23373
75. M. Anand K. Rajagopal K. R. Rajagopal A model for the formation and lysis of blood clots Pathophysiol. Haemostasis Thromb. 2005 34 109 120
76. M. Anand K. Rajagopal K. R. Rajagopal A model incorporating some of the mechanical and biochemical factors underlying clot formation and dissolution in flowing blood Journal of Theoretical Medicine 2003 5 183 218
77. M. F. Hockin K. C. Jones S. J. Everse K. G. Mann A model for the stoichiometric regulation of blood coagulation J. Biol. Chem. 2002 277 18322 18333
78. C. Igel N. Hansen S. Roth Covariance matrix adaptation for multi-objective optimization Evol. Comput. 2007 15 1 28
79. C. Fonseca P. Fleming An Overview of Evolutionary Algorithms in Multiobjective Optimization Evol. Comput. 1995 3 1 16
80. D. Battogtokh D. K. Asch M. E. Case J. Arnold H. B. Schuttler An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of neurospora crassa Proc. Natl. Acad. Sci. U. S. A. 2002 99 16904 16909
81. S. R. Coughlin How the protease thrombin talks to cells Proc. Natl. Acad. Sci. U. S. A. 1999 96 11023 11027
82. C. T. Esmon The roles of protein C and thrombomodulin in the regulation of blood coagulation J. Biol. Chem. 1989 264 4743 4746
83. W. H. Kane P. W. Majerus The interaction of human coagulation factor Va with platelets J. Biol. Chem. 1982 257 3963 3969
84. S. S. Ahmad R. Rawala-Sheikh P. N. Walsh Platelet receptor occupancy with factor IXa promotes factor X activation J. Biol. Chem. 1989 264 20012 20016
85. S. S. Ahmad J. M. Scandura P. N. Walsh Structural and functional characterization of platelet receptor-mediated factor VIII binding J. Biol. Chem. 2000 275 13071 13081
86. R. J. Leipold T. A. Bozarth A. L. Racanelli I. B. Dicker Mathematical model of serine protease inhibition in the tissue factor pathway to thrombin J. Biol. Chem. 1995 270 25383 28387
87. C. Veer N. J. Golden M. Kalafatis K. G. Mann Inhibitory mechanism of the protein C pathway on tissue factor-induced thrombin generation J. Biol. Chem. 1997 272 7983 7994
88. P. A. Kr von dem Borne J. C. M. Meijers B. N. Bouma Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis Blood 1995 86 3035 3042
89. C. Dellas D. J. Loskutoff Historical analysis of pai-1 from its discovery to its potential role in cell motility and disease Thromb. Haemostasis 2005 93 631 640
90. D. C. Rijken E. Hoegee-De Nobel A. F. H. Jie D. E. Atsma M. J. Schalij et al., Development of a new test for the global fibrinolytic capacity in whole blood J. Thromb. Haemostasis 2007 6 151 157
91. P. Bjorquist M. Brohlin J. Ehnebom M. Ericsson C. Kristiansen et al., Plasminogen activator inhibitor type-i interascs exclusively with the proteinase domain of tissue plasminogen activator Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1994 1209 191 202
92. C. Thelwell C. Longstaff The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1 J. Thromb. Haemostasis 2007 5 804 811
93. S. Thorsen M. Philips J. Selmer I. Lecander B. Astedt Kinetics of inhibition of tissue-type and urokinase-type plassminogen activator by plasminogen-activator inhibitor type 1 and type 2 Eur. J. Biochem. 1988 175 33 39
94. M. Ranby Studies on the kinetics of plasminogen activation by tissure plasminogen activator Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1982 704 461 469
95. E. L. Madison G. S. Coombs D. R. Corey Substrate specificity of tissure type plasminogen activator J. Biol. Chem. 1995 270 7558 7562
96. V. Ellis N. Behrendt K. Dano Plasminogen activation by receptor-bound urokinase J. Biol. Chem. 1991 266 12752 12758
97. B. Wiman D. Collen On the kinetics of the reaction between human antiplasmin and plasmin Eur. J. Biochem. 1978 84 573 578
98. U. Christensen K. Bangert S. Thorsen Reaction of human a2-antiplasmin and plasmin stopped-flow fluorescence kinetics Biochem. J. 1995 305 97 102
99. M. Ries R. L. Easton C. Longstaff M. Zenker H. R. Morris et al., Differences between neonates and adults in carbohydrate sequences and reaction kinetics of plasmin and a2-antiplasmin Thromb. Res. 2002 105 247 256
100. M. Ries M. Zenker Influence of soluble fibrin on reaction kinetics of plasmin type 1 and type 2 with a2-antiplasmin Blood Coagulation Fibrinolysis 2003 14 203 209
101. K. Kolev I. Lerant K. Tenekejiev R. Machovich Regulation of fibrinolytic activity of neutrophil leukocyte elastase, plasmin, and miniplasmin by plasma protease inhibitors J. Biol. Chem. 1994 269 17030 17034
102. S. W. Hall J. E. Humphries S. L. Gonias Inhibition of cell surface receptor-bound plasmin by a2-antiplasmin and a2-macroglobulin J. Biol. Chem. 1991 266 12329 12336
103. J. P. De Boer A. A. Creasey A. Chang J. J. Abbink D. Roem et al., Alpha-2-macroglobulin fuctions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: Studies using a baboon model Infection and Immunity 1993 61 5035 5043
104. M. Schneider M. Nesheim A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis J. Biol. Chem. 2004 279 13333 13339
105. M. Schneider N. Brufatto E. Neill M. Nesheim Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation procuctions to protect plasmin from antiplasmin J. Biol. Chem. 2004 279 13340 13345
106. N. J. Mutch N. R. Moore E. Wang N. A. Booth Thrombus lysis by upa, scupa and tpa is regulated by plasma tafi J. Thromb. Haemostasis 2003 1 2000 2007
107. M. B. Boffa W. Wang L. Bajzar M. E. Nesheim Plasma and recombinant tafi and activated tafi compared with respect to glycosylation, thrombin/ thrombomodulindepent activation J. Biol. Chem. 1998 273 2121 2135
108. U. Scheefers-Borchel G. Muller-Berghaus P. Fuhge R. Eberle N. Heimburger Discrimination between fibrin and fibrinogen by a monoclonal antibody against a synthetic peptide Proc. Natl. Acad. Sci. U. S. A. 1985 82 7091 7095 (Pubitemid 16209698)
109. S. Olson I. Bjork R. Sheffer P. A. Craig J. D. Shore et al., Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombinproteinase reactions. resolution of the antithrombin conformational change contribution to heparin rate enhancement J. Biol. Chem. 1992 267 2528 2538
110. N. T. Ansani Fondaparinux: The first pentasaccharide anticoagulant PT 2002 27 310 315
111. M. A. Parry J. M. Maraganore S. R. Stone Kinetic mechamism for the interaction of hirulog with thrombin Biochemistry 1994 33 14807 14814
112. M. Elg D. Gustafsson J. Deinum The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis Thromb Haemost 1997 78 1286 1292
113. K. A. Tanaka F. Szlam J. Vinten-Johansen A. D. Cardin J. H. Levy Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan Thromb. Haemostasis 2005 94 1 6
114. J. H. Lawson S. Butenas N. Ribarik K. G. Mann Complex-dependent inhibition of factor viia by antithrombin iii and heparin J. Biol. Chem. 1993 268 767 770
115. F. Espana M. Berrettini J. H. Griffin Purification and characterization of plasma protein c inhibitor Thromb. Res. 1989 55 369 384